Glucagon‐like peptide‐1 receptor agonists and alcohol use disorders: An emerging unexpected beneficial effect
Pooled result · Prevalence of AUDResult — go to the resultHazard ratio 0.65 95% CI 0.56–0.74Authors' conclusion
In conclusion, available data from observational cohort studies showed a concordant and significantly reduced risk of AUD and alcohol consumption habits with GLP-1RA therapy.
Study context
- Population
- Obese/T2D patients treated with GLP-1 RAs compared with a control group7 observational cohort studies
- Comparison
- GLP-1 RA therapy vs no GLP-1 therapy
- Outcome
- Prevalence of AUD
Methodological detailsextensive literature search
- Extensive literature search
Pooled result
As reported in the abstract
Hazard ratio
0.65
95% CI 0.56–0.74
GLP-1 RAvs No GLP-1 therapy
HR 0.65 (95% CI 0.56–0.74)
Further pooled results
RCTs of GLP-1 RAs in alcohol use disorders (AUD)
- Only 2 RCTs available, with inconclusive results; several ongoing (semaglutide)
Original publication
Glucagon‐like peptide‐1 receptor agonists and alcohol use disorders: An emerging unexpected beneficial effect. Diabetes Obes Metab. Published 13 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →